COSMO Pharmaceuticals SA Working Capital to Net Assets Ratio
COSMO Pharmaceuticals SA working capital to net assets ratio. COSMO Pharmaceuticals SA (0RGI) has a Working Capital to Net Assets ratio of 41.6% as of June 2026. Working capital of £238.62 Million (current assets of £263.32 Million minus current liabilities of £24.70 Million) is measured against net assets of £573.73 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible equity quality of COSMO Pharmaceuticals SA to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of COSMO Pharmaceuticals SA (2004–2025)
Working capital to net assets ratio of COSMO Pharmaceuticals SA from 2004 to 2025. This chart shows how COSMO Pharmaceuticals SA's Working Capital to Net Assets ratio has evolved across 22 annual periods from 2004 to 2025. As of June 2026, the ratio stands at 41.6%, reflecting working capital of £238.62 Million against net assets of £573.73 Million GBP. See defensive interval ratio of COSMO Pharmaceuticals SA to measure how many days the company can operate on defensive assets alone.
COSMO Pharmaceuticals SA Working Capital to Net Assets Ratio by Year (2004–2025)
COSMO Pharmaceuticals SA working capital to net assets ratio by year from 2004 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for COSMO Pharmaceuticals SA from 2004 to 2025, covering 22 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see COSMO Pharmaceuticals SA assets under control.
| Year | WC/NA Ratio | Working Capital (GBP) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 32.2% | £157.63 Million | £488.80 Million | £183.14 Million | £25.50 Million | ▲ +1.8 pp |
| 2024 | 30.5% | £153.99 Million | £505.09 Million | £202.26 Million | £48.27 Million | ▲ +12.7 pp |
| 2023 | 17.8% | £76.51 Million | £429.04 Million | £102.23 Million | £25.71 Million | ▼ -6.1 pp |
| 2022 | 24.0% | £111.15 Million | £463.79 Million | £306.10 Million | £194.95 Million | ▼ -25.7 pp |
| 2021 | 49.7% | £254.61 Million | £512.68 Million | £275.85 Million | £21.24 Million | ▼ -8.1 pp |
| 2020 | 57.8% | £231.07 Million | £400.12 Million | £252.87 Million | £21.79 Million | ▼ -15.1 pp |
| 2019 | 72.8% | £286.66 Million | £393.73 Million | £302.37 Million | £15.71 Million | ▼ -7.9 pp |
| 2018 | 80.7% | £358.82 Million | £444.85 Million | £374.17 Million | £15.35 Million | ▲ +42.8 pp |
| 2017 | 37.8% | £177.87 Million | £470.12 Million | £197.31 Million | £19.43 Million | ▼ -2.7 pp |
| 2016 | 40.5% | £168.36 Million | £415.56 Million | £187.07 Million | £18.72 Million | ▲ +12.5 pp |
| 2015 | 28.0% | £112.89 Million | £403.65 Million | £137.93 Million | £25.04 Million | ▲ +21.4 pp |
| 2014 | 6.6% | £10.05 Million | £152.29 Million | £70.71 Million | £60.66 Million | ▼ -74.5 pp |
| 2013 | 81.1% | £178.63 Million | £220.16 Million | £188.33 Million | £9.70 Million | ▲ +59.0 pp |
| 2012 | 22.2% | £33.32 Million | £150.41 Million | £48.26 Million | £14.94 Million | ▼ -6.7 pp |
| 2011 | 28.8% | £18.29 Million | £63.43 Million | £28.60 Million | £10.31 Million | ▲ +1.0 pp |
| 2010 | 27.8% | £16.23 Million | £58.37 Million | £43.44 Million | £27.21 Million | ▼ -9.9 pp |
| 2009 | 37.7% | £22.54 Million | £59.80 Million | £29.83 Million | £7.29 Million | ▼ -18.5 pp |
| 2008 | 56.2% | £24.31 Million | £43.24 Million | £33.69 Million | £9.38 Million | ▼ -20.8 pp |
| 2007 | 77.1% | £27.09 Million | £35.15 Million | £33.67 Million | £6.58 Million | ▲ +106.5 pp |
| 2006 | -29.5% | £-1.57 Million | £5.34 Million | £9.98 Million | £11.56 Million | ▲ +579.4 pp |
| 2005 | -608.9% | £-3.84 Million | £631.00K | £8.30 Million | £12.15 Million | ▼ -1018.6 pp |
| 2004 | 409.8% | £-3.61 Million | £-880.00K | £4.14 Million | £7.75 Million | — |